抗rna免疫治疗心脏:治疗学的新前沿。

Q4 Medicine
Cardiology Plus Pub Date : 2025-04-01 Epub Date: 2025-06-24 DOI:10.1097/CP9.0000000000000116
Joel Gregory Rurik, Christian Le Phu, Julian Mustroph, Marcus Buggert
{"title":"抗rna免疫治疗心脏:治疗学的新前沿。","authors":"Joel Gregory Rurik, Christian Le Phu, Julian Mustroph, Marcus Buggert","doi":"10.1097/CP9.0000000000000116","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular diseases remain the leading cause of death worldwide. Despite significant progress and the development of numerous effective drugs, substantial morbidity and mortality persist. This review highlights one potentially fruitful avenue for discovering novel therapeutics: leveraging ribonucleic acid (RNA) to tip the immunological balance toward tissue repair. Decades of research have primed the three disciplines of cardiology, immunology, and RNA drug development, to bring potent intersectional therapies to the clinic. We discuss both coding and non-coding RNA interventions across multiple cell types, such as monocytes, macrophages, and T cells, throughout different cardiovascular diseases. Altogether, advanced RNA-based medicines targeting the immune system are primed to transform how cardiovascular diseases are treated.</p>","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"10 2","pages":"129-144"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12208391/pdf/","citationCount":"0","resultStr":"{\"title\":\"RNA-ssisting immunity to heal the heart: a new frontier in therapeutics.\",\"authors\":\"Joel Gregory Rurik, Christian Le Phu, Julian Mustroph, Marcus Buggert\",\"doi\":\"10.1097/CP9.0000000000000116\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cardiovascular diseases remain the leading cause of death worldwide. Despite significant progress and the development of numerous effective drugs, substantial morbidity and mortality persist. This review highlights one potentially fruitful avenue for discovering novel therapeutics: leveraging ribonucleic acid (RNA) to tip the immunological balance toward tissue repair. Decades of research have primed the three disciplines of cardiology, immunology, and RNA drug development, to bring potent intersectional therapies to the clinic. We discuss both coding and non-coding RNA interventions across multiple cell types, such as monocytes, macrophages, and T cells, throughout different cardiovascular diseases. Altogether, advanced RNA-based medicines targeting the immune system are primed to transform how cardiovascular diseases are treated.</p>\",\"PeriodicalId\":52908,\"journal\":{\"name\":\"Cardiology Plus\",\"volume\":\"10 2\",\"pages\":\"129-144\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12208391/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiology Plus\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/CP9.0000000000000116\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology Plus","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CP9.0000000000000116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

心血管疾病仍然是全世界死亡的主要原因。尽管取得了重大进展并开发了许多有效药物,但大量发病率和死亡率仍然存在。这篇综述强调了发现新疗法的一个潜在的富有成效的途径:利用核糖核酸(RNA)来打破组织修复的免疫平衡。经过几十年的研究,心脏病学、免疫学和RNA药物开发这三个学科已经为临床带来了强有力的交叉疗法。我们讨论了编码和非编码RNA干预跨多种细胞类型,如单核细胞,巨噬细胞和T细胞,在不同的心血管疾病。总之,以免疫系统为目标的先进rna药物将改变心血管疾病的治疗方式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

RNA-ssisting immunity to heal the heart: a new frontier in therapeutics.

RNA-ssisting immunity to heal the heart: a new frontier in therapeutics.

RNA-ssisting immunity to heal the heart: a new frontier in therapeutics.

RNA-ssisting immunity to heal the heart: a new frontier in therapeutics.

Cardiovascular diseases remain the leading cause of death worldwide. Despite significant progress and the development of numerous effective drugs, substantial morbidity and mortality persist. This review highlights one potentially fruitful avenue for discovering novel therapeutics: leveraging ribonucleic acid (RNA) to tip the immunological balance toward tissue repair. Decades of research have primed the three disciplines of cardiology, immunology, and RNA drug development, to bring potent intersectional therapies to the clinic. We discuss both coding and non-coding RNA interventions across multiple cell types, such as monocytes, macrophages, and T cells, throughout different cardiovascular diseases. Altogether, advanced RNA-based medicines targeting the immune system are primed to transform how cardiovascular diseases are treated.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
24
审稿时长
32 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信